Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial

Jørgen Gravning1, Stein Ørn, Ole Jørgen Kaasbøll

  • 1Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Plos One
|January 4, 2013
PubMed
Abstract

Insights

Cardiac Connective Tissue Growth Factor (CTGF) reduces adverse cardiac remodeling and improves heart function after myocardial infarction (MI). This study shows CTGF attenuates inflammation and apoptosis, leading to better outcomes in mice and humans.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Regenerative Medicine

Background:

  • Connective Tissue Growth Factor (CTGF) is upregulated in heart failure.
  • The specific role of CTGF in myocardial infarction (MI) and subsequent left ventricular (LV) remodeling is not fully understood.

Purpose of the Study:

  • To investigate the role of CTGF in infarct healing and LV remodeling post-MI.
  • To explore CTGF's impact on cardiac function and survival in a mouse model and human patients.

Main Methods:

  • Utilized transgenic mice overexpressing cardiac CTGF and subjected them to coronary artery ligation.
  • Assessed infarct size, cardiac hypertrophy, LV dilatation, LV function, and mortality.
  • Monitored serum CTGF levels in ST-elevation MI patients undergoing PCI, correlating with cardiac MRI findings.

Main Results:

  • Overexpression of CTGF in mice led to smaller scar tissue, reduced hypertrophy, less LV dilatation, and improved LV function 4 weeks post-MI.
  • Tg-CTGF mice exhibited significantly lower mortality rates after MI.
  • In patients, increased serum CTGF post-MI correlated with reduced infarct size, improved LV ejection fraction, and lower inflammatory markers (CRP, GDF-15).

Conclusions:

  • Elevated myocardial CTGF activity post-MI is linked to attenuated LV remodeling and enhanced LV function.
  • These beneficial effects appear to be mediated by reduced inflammatory responses and inhibition of apoptosis.
  • CTGF shows potential as a therapeutic target for improving outcomes after myocardial infarction.